Resilience Software Specialist Restrata Secures Growth Investment From SEP
13.2.2025 02:01:00 EET | Business Wire | Press release
Restrata, the operational resilience software and service provider to global enterprises, including some of the world’s largest energy and industrial companies, has raised investment from Scottish Equity Partners (SEP) to meet growing market demand.
The investment will support accelerated product development and AI-powered enhancements as well as expansion of existing operations in North America, Europe, and the Middle East.
Increased adoption of the London-based company’s resilienceOS platform, which helps enterprise clients protect their people, assets and operations globally, saw resilienceOS revenue surge more than 50% in 2024.
Enterprises are increasingly focused on people safety and operational resilience due to unprecedented levels of global uncertainty. In response, business leaders are seeking sophisticated technology to mitigate, manage, and respond to operational disruption while maintaining visibility and control over day-to-day operations. These threats range from localised industrial accidents and targeted physical security issues to large scale political instability and security risks, industrial and road safety, extreme weather and natural disasters, as well as organised crime or lone wolf attacks. Spend on solutions such as resilienceOS is growing rapidly, with the multi-billion-dollar market growing more than 10% each year.
The company has been serving the security and safety needs of organisations operating globally, including in high-risk locations, since 2006. Co-founders Chris St George (Chair) and Botan Osman (CEO) combined their technology, security, military and government experience to create a better way for companies to protect people and operations, powered by software.
“We built resilienceOS to solve the challenge of relying on fragmented security systems to protect people and operations,” said Botan Osman. “Security and resilience teams want to focus on what matters most and need software to act as a force multiplier. Customers, employees, and shareholders expect leaders to adopt technology that safeguards people and protects businesses.”
Chris St George added: “resilienceOS is changing the way the world’s largest companies manage safety and security. In particular, the bespoke functionality designed for the energy sector is transforming duty of care in remote, offshore and high-risk markets — ultimately protecting assets, preventing injury and saving lives.”
Customers now use resilienceOS to power global security operation centres (GSOCS) around the world, managing incidents and crises, protecting global travellers everywhere, enabling people safety, monitoring lone workers, and protecting assets.
“resilienceOS is a fully unified platform, with an open ecosystem, working from a common customer data set to more effectively respond to critical events as they happen. The unified and open nature of the platform is unique in the market, and is the key reason why some of the most complex global customers are now choosing resilienceOS,” Osman continued.
“We are delighted to be partnering with the Restrata team to help build on the business’ current momentum,” added Tim Ankers, Director at SEP. “The company has developed a strong product and international customer base. The market tailwinds are clear and Restrata’s resilienceOS product is uniquely placed to serve the increasingly sophisticated security needs of global enterprises.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212395778/en/
Contacts
for SEP
Jen Richards
jen.richards@hottinroof.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom